Skip to main content
MAZE logo

MAZE · Maze Therapeutics, Inc.

Track MAZE — free
$29.58 -0.84 (-2.76%) At close · Aug 26
Market Cap
$1.65B
Shares
55.55M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$167.5M
FY2024
Net Income
-$131.12M -351%
FY2025 Net Income FY2024–FY2025
Operating Margin
34.38%
FY2024
Diluted EPS
-$3.05 -344%
FY2025 Diluted EPS FY2024–FY2025
Operating Cash Flow
-$111.94M -247.4%
FY2025 Operating Cash Flow FY2024–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024
$167.5M
$121.85M $108.45M $83.5M
$43.76M $34.45M $26.42M
$165.61M $142.9M $109.91M
-$145.61M -$142.9M $57.59M
34.38%
-$131.12M $53.4M
$0 $1.17M
-$133.59M -$131.12M $52.23M
31.18%
-$131.12M $3.41M
-$134.03M -$131.01M $52.23M
USD/shares -$3.05 $1.42
USD/shares -$3.05 $1.25
shares 42.98M 2.4M
shares 42.98M 2.73M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Peer median 7.40×
EV/EBIT
Peer median 12.45×
P/E (TTM)
Peer median 17.78×

Peer medians compare against the 272 similar-size Biotechnology companies (of 534 listed).

Key facts CIK 1842295 CUSIP 578784100 13F (30d) 151 filings 150 filers Visit website Investor relations